Nicotinic Receptor Levels After Stopping Smoking

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This positron emission tomography (PET) study examines the effects of 24 hours abstinence from smoking on return to availability of neuronal nicotinic receptors in slow and fast metabolizers of nicotine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nicotine Metabolizers and [11C]-(+)-PHNO

NCT02514720

Nicotine Dependence

COMPLETED NA

Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction

NCT03442413

Smoking, Tobacco

ACTIVE_NOT_RECRUITING PHASE1

Nicotine Receptor Levels and Smoking Cessation

NCT01788943

Smoking Cessation Nicotine Addiction

COMPLETED

Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers

NCT01038245

Nicotine Addiction

COMPLETED

Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors

NCT04258852

Electronic Cigarette Use

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The nicotine metabolite ratio (NMR), a stable marker of nicotine clearance rate, is a robust predictor of smoking relapse. Individuals who are fast nicotine metabolizers have higher rates of relapse, compared to slow metabolizers, on nicotine replacement or placebo treatment. Nicotine exerts its reinforcing properties, in part, by binding to α4β2\* nicotinic acetylcholine receptors (nAChRs) in the brain. The α4β2\* nAChRs are abundant and have high affinity for nicotine relative to other nAChR subtypes. The goal of this project is to identify abstinence-induced changes in neuronal nicotinic receptor availability that may underlie risk for smoking relapse.

The investigators propose to utilize positron emission tomography (PET) imaging to examine the association of variation in nicotine metabolism with return to availability of α4β2\* nAChRs during early abstinence. The investigators will measure α4β2\* receptor availability using the PET radio-ligand 2-\[18F\]FA, administered with bolus injection, on two separate occasions: during smoking as usual and after 24 hours of abstinence. The proposed study will help us understand the neurochemical mechanisms that underlie the higher risk of relapse among faster nicotine metabolizers, thereby pointing to potential targets for tailored therapy for these smokers at increased risk.

In addition, the investigators will invite six subjects who have completed the two PET scans described above to complete a third PET scan. During this third PET scan, the investigators plan to measure α4β2\* receptor availability using the PET radio-ligand 2-\[18F\]FA, administered as bolus plus constant infusion after 24 hours of abstinence. The purpose will be to compare α4β2\* nAChR binding potential data from the bolus 2-\[18F\]FA infusion protocol used in the main study to the bolus plus constant infusion protocol used in this third PET scan.

The protocol of this third PET scan will help the investigators demonstrate the feasibility at the University of Pennsylvania of administering the radiotracer as a bolus plus constant infusion, and the feasibility of scanning for two hours (versus one hour in the current protocol) paradigm. This data is important pilot data for future NIH grant submissions using this radiotracer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Addiction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NMR by abstinence status

This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2\* nAChR availability using 2-\[18F\]-fluro-3-\[2(S)-2-azethidinylmethoxy\]-pyridine (2-\[18F\]FA) PET imaging.

Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.

All participants who complete both PET scans will also complete an anatomical MRI scan.

2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine

Intervention Type DRUG

The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.

2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine

The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.

2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

2-[18F]FA, 2-FA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ages 18 to 65 years old.
2. Smoke 10 cigarettes per day for the previous 6 months.
3. Weigh less than 300lbs (due to limitations of the PET and MRI scanners).

Exclusion Criteria

1. Smoking behavior:

1. Current enrollment or plans to enroll in a smoking cessation program, or use other smoking cessation medications in the next 2 months.
2. Provide a CO reading of less than 10 ppm at medical screening.
2. Alcohol/Drugs:

1. History of substance abuse and/or currently receiving treatment for substance abuse (e.g., alcohol, opioids, cocaine, marijuana, or stimulants).
2. Positive drug screen at any of the sessions (see page 8 for list of drugs and/or contra-indicated medications).
3. Current alcohol consumption that exceeds 25 standard drinks/week.
4. Providing a breath alcohol concentration (BrAC) reading of greater than or equal to 0.01 at any session.
3. Medical:

1. Women who are pregnant, planning a pregnancy, or lactating; all female subjects shall undergo a serum pregnancy test at the medical screening session and urine pregnancy tests at the two PET scans and MRI scan.
2. Women of child-bearing age must agree in writing to use an approved method of contraception or agree to abstain from sexual intercourse
3. History or current diagnosis of the following psychiatric diagnoses identified by the MINI (Mini International Neuropsychiatric Interview) such as psychosis, bipolar disorder, schizophrenia, major current depression, or any Axis 1 disorder
4. Self-report of serious or unstable disease within the past 6 months (e.g., cancer \[except melanoma\], HIV/AIDS, stroke, angina, coronary disease, heart attack).
5. History of epilepsy or a seizure disorder.
6. Any medical or neurological condition that might interfere with the distribution of the radiotracer as determined by the study M.D.
4. Medication:

a. Current use or recent discontinuation (within last 14-days) of the following medications:
* Any form of smoking cessation medication (Zyban, Wellbutrin, Wellbutrin SR, Chantix, NRT);
* Recent (within last 14 days) or planned use of psychotropic medications (anti-psychotics, anti-depressants, anti-anxiety, anti-panic medications, mood stabilizers, opioids, and stimulants).
* Participants shall be instructed to refrain from using any study prohibited drugs (note - participants are allowed to take prescription medicines not in the exclusion list) throughout their participation in the study.

1. Self-reported history of head trauma or brain (or CNS) tumor.
2. Self-reported history of claustrophobia (contraindicated for PET and MRI).
3. Having a cochlear implant or wearing bilateral hearing aids.
4. Self-reported use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for MRI.
5. History of gunshot wound.
6. Circumstances or conditions that may interfere with magnetic resonance imaging (MRI)
7. Inability to complete the baseline study procedures within four hours and/or correctly, as determined by the PI.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No